Biotechnology

Bicycle Therapeutics

Bicycle Therapeutics released FY2026 Q1 earnings on April 30 (EST), actual revenue USD 887K (forecast USD 7.499M), actual EPS USD -0.8728 (forecast USD -0.6962)

Oppenheimer Downgrades Bicycle Therapeutics Target Price to $36

Bicycle Therapeutics released FY2025 Q4 earnings on March 17 (EST), actual revenue USD 47.96 M (forecast USD 7.076 M), actual EPS USD -0.2905 (forecast USD -0.9536)

Bicycle Therapeutics released FY2025 annual earnings on March 17 (EST), actual revenue USD 72.59 M (forecast USD 32.18 M), actual EPS USD -3.1605 (forecast USD -3.879)

Bicycle Therapeutics plc CFO Disposes of Ordinary Shares

Lawson Focuses on Healthcare Sector and Key Stocks

Bicycle Therapeutics released FY2025 9 Months Earnings on October 30 EST, with actual revenue of USD 24.63 M and EPS of USD -2.8708

Bicycle Therapeutics released FY2025 Q3 earnings on October 30 (EST), actual revenue USD 11.73 M (forecast USD 8.25 M), actual EPS USD -0.8527 (forecast USD -1.0981)

Bancroft Covers Healthcare Sector and Rates Specific Stocks

Bicycle Therapeutics Unveils Precision Oncology Innovation Presentation

Bicycle Therapeutics released FY2025 Semi-Annual earnings on August 8 (EST), actual revenue USD 12.9 M, actual EPS USD -2.0181

Bicycle Therapeutics released FY2025 Q2 earnings on August 8 (EST), actual revenue USD 2.92 M (forecast USD 9.429 M), actual EPS USD -1.14 (forecast USD -0.9581)

FactSet Analysts Give Bicycle Therapeutics an Outperform Rating

Bicycle Therapeutics reports Nasdaq listing rule inducement grant

Bicycle Therapeutics to Present Zelenectide Pevedotin Study at ASCO Annual Meeting

Bicycle Therapeutics plc Grants Inducement Options to 13 New Employees

Bicycle Therapeutics Misses Earnings Expectations

Bicycle Therapeutics released FY2025 Q1 earnings on May 1 (EST), actual revenue USD 9.977 M (forecast USD 8.673 M), actual EPS USD -0.8779 (forecast USD -0.8477)

Bicycle Therapeutics 2025 Q1 Earnings Report

Bicycle Therapeutics Inc posts increased Q1 net loss

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

BCYC

Bicycle Therapeutics reported initial Duravelo-2 data for zelenectide in metastatic urothelial cancer, showing a 65% unconfirmed overall response rate (ORR) and a favorable safety profile. Key findings include a median treatment duration of 6.3 months, with 65% of patients still on treatment. Cohort 2 showed a 37% ORR. Updated Duravelo-1 data indicated a 59% unconfirmed ORR and median progression-free survival of 13.0 months.

TradingView

Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | BCYC Stock News

StockTitan

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | BCYC Stock News

Needham's Ami Fadia has reaffirmed a Buy rating on Bicycle Therapeutics (BCYC) with a price target of $15.00. Fadia, who specializes in the Healthcare sector, has an average return of 30.8% and a 56.80% success rate on stock recommendations. Additionally, TD Cowen's Tara Bancroft also rated BCYC as a Buy, while Truist Financial maintained a Hold rating on the stock.

Tip Ranks

Needham Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)

TD Cowen analyst Tara Bancroft has initiated a Buy rating on BCYC stock, citing the promising efficacy of nuzefatide in treating metastatic urothelial cancer and advancements in pancreatic cancer trials. The strong response rates in EV-naïve patients suggest nuzefatide could be a differentiated treatment option. Additionally, the Phase II trial for pancreatic cancer has begun dosing with an optimized dose, supported by preclinical data. Needham also reiterated a Buy rating with a $15 price target. Bancroft has a 27.1% average return and a 51.23% success rate on her stock recommendations.

- TD Cowen analyst Tara Bancroft has maintained a bullish stance on BCYC stock, assigning it a buy rating today.  
- The rating is supported by positive early efficacy results of nuzefatide in metastatic urothelial carcinoma, alongside promising developments in pancreatic cancer research.  
- Needham also reiterated a buy rating on the stock with a price target of $15.00.

Ocular Therap

Nanobiotix SA

Day One Biopharmaceuticals

Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program

Earnings Watch

Bicycle Therapeutics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 887 K

Bicycle Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 887 K

Bicycle Therapeutics | 10-K: FY2025 Revenue Beats Estimate at USD 72.59 M

Bicycle Therapeutics plc (NASDAQ: BCYC) announced its participation in the 2026 ASCO Annual Meeting, featuring an oral presentation and multiple poster presentations on its innovative therapeutics. Key presentations include interim analysis results from studies on zelenectide pevedotin (BT8009) in patients with advanced urothelial carcinoma. The meeting will take place from May 29 to June 2 in Chicago, with details available on the company's website.

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting | BCYC Stock News

Bicycle Therapeutics received a Buy rating from Needham analyst Ami Fadia, who set a $15.00 price target. The positive outlook is based on promising early clinical data for nuzefatide pevedotin, showing a 100% response rate in EphA2-positive metastatic urothelial carcinoma patients. Initial results in pancreatic cancer and supportive preclinical findings in head and neck squamous cell carcinoma suggest significant expansion potential. Investors are also looking forward to detailed Phase 2 results for zelenectide pevedotin, reinforcing Fadia's optimistic view on the company's valuation and growth prospects.

- Bicycle Therapeutics, a healthcare company, is currently in the spotlight among Wall Street analysts, with Needham's Ami Fadia reaffirming a "buy" rating and a target price of $15.00.  
- Fadia's positive outlook is based on encouraging early clinical data for its asset nuzefatide pevedotin, which showed a 100% response rate in patients with metastatic uroepithelial carcinoma when combined with nivolumab.  
- Additionally, promising preliminary data in pancreatic cancer and supportive findings in head and neck squamous cell carcinoma suggest significant expansion potential, bolstering investor confidence in the company's valuation and growth prospects.

Bicycle Therapeutics: Early EphA2-Targeted Data and Multi-Tumor Expansion Potential Support Buy Rating and Upside to Valuation

Bicycle Therapeutics(BCYC.US)

Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | BCYC Stock News

Needham Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)

Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program

Bicycle Therapeutics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 887 K

Bicycle Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 887 K

Bicycle Therapeutics | 10-K: FY2025 Revenue Beats Estimate at USD 72.59 M

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting | BCYC Stock News

Bicycle Therapeutics: Early EphA2-Targeted Data and Multi-Tumor Expansion Potential Support Buy Rating and Upside to Valuation